Adelis completed the investment in IonOpticks.

Adelis, a private equity firm, completed the investment in IonOpticks, a proteomics tools company. Financial terms were not disclosed. “We chose to partner with Adelis because they share our vision for IonOpticks' goals and are a strong cultural fit. Their genuine desire to work with us and guide the company to realise its goals, together with their experience, networks, and resources, made them the ideal partner. This partnership allows us to continue developing the best chromatography solutions for researchers worldwide and pursue further innovations tailored to the industry's evolving needs,” Xavier Perronnet, IonOpticks Chief Executive Officer.